Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 5, 2025
Product Development
Biotechs make inroads to precision medicine, solving long-standing problems
70% of new precision medicines approved by FDA in past three years were not sponsored by major pharmas
BioCentury | Aug 2, 2024
Finance
Public Equity Report: Day One’s PIPE, Heartseed’s Tokyo listing
Few deals amid selloff, fears of volatility
BioCentury | Jul 29, 2024
Deals
Deals Report: GSK is latest pharma to draw on Flagship portfolio
Plus: Day One’s ex-U.S. deal with Ipsen; Novartis taps Dren Bio’s oncology platform; BI buys Avalon-backed Nerio; and Collegium’s ADHD takeout
BioCentury | Jun 27, 2024
Product Development
Solving for the medical and business case in pediatric cancer — Day One
CEO Jeremy Bender on building a strategy for pediatric cancer therapies that serves both patients and investors
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
BioCentury | Apr 3, 2024
Deals
With $1.8B ProfoundBio deal, Genmab gains chance to market ‘100% owned’ product
Along with ADC platform, the Danish antibody specialist gains a FOLR1-targeting product entering pivotal testing for ovarian cancer
BioCentury | Feb 16, 2024
Finance
Venture report: Earlybird’s €173M fund, launches for Firefly and Latigo
European VC closes new vehicle; start-ups backed by Versant, Westlake Village out of stealth; Medicxi’s bundle; rounds for Freenome, ProfoundBio
BioCentury | Apr 21, 2023
Product Development
ADC advances at AACR: target diversity, optimizing internalization
BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | Mar 18, 2021
Deals
Led by ex-Springworks exec, Pyxis forges deal to gain access to Pfizer’s ADCs, platform tech
Pyxis CEO Lara Sullivan has struck a deal with her former employer, Pfizer, that adds two preclinical therapies to the biotech’s pipeline as well as a license to the pharma’s ADC
Items per page:
1 - 10 of 16